EDITORIAL
Published on 06 Jul 2023
Editorial: Ex-vivo and in-vivo genome engineering for metabolic and neurometabolic diseases
doi 10.3389/fgeed.2023.1248904
- 1,538 views
- Frontiers in Genome Editing
- Genome Editing in Human Health and Disease
- Research Topics
- Ex-Vivo and In-Vivo Genome Engineering for Metabolic and Neurometabolic Diseases
Ex-Vivo and In-Vivo Genome Engineering for Metabolic and Neurometabolic Diseases
7,197
Total downloads
27k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
REVIEW
Published on 09 Jan 2023
Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders
doi 10.3389/fgeed.2022.997142
- 5,183 views
- 7 citations
REVIEW
Published on 17 May 2022
Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich’s Ataxia
doi 10.3389/fgeed.2022.903139
- 8,318 views
- 18 citations
ORIGINAL RESEARCH
Published on 11 Mar 2022
Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice
doi 10.3389/fgeed.2022.785698
- 3,920 views
- 13 citations
MINI REVIEW
Published on 25 Nov 2021
Prime Editing for Inherited Retinal Diseases
doi 10.3389/fgeed.2021.775330
- 6,524 views
- 22 citations
Published in
Frontiers in Genome Editing
- Genome Editing in Human Health and Disease
- Genome Engineering and Neurologic DisordersOffline
- Genome Editing in Blood DisordersOffline
Impact
- 27kTopic views
- 19kArticle views
- 7,197Article downloads